Stablecoin Development Corp DEF 14A, filed Apr 16, 2009: NOVABAY PHARMACEUTICALS DEF 14A 6-4-2009
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
14A
Proxy
Statement Pursuant to Section 14(a) of
the
Securities Exchange Act of 1934 (Amendment No. ___)
Filed by
the Registrant ⌧
Filed by
a Party other than the Registrant □
Check the
appropriate box:
|
□
|
Preliminary
Proxy Statement
|
|
□
|
Confidential, For Use of the
Commission Only (as permitted by Rule
14a-6(e)(2))
|
|
⌧
|
Definitive
Proxy Statement
|
|
□
|
Definitive
Additional Materials
|
|
□
|
Soliciting
Material Pursuant to §240.14a-12
|
NovaBay
Pharmaceuticals, Inc.
(Name of
Registrant as Specified in Its Charter)
(Name of
Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment
of Filing Fee (Check the appropriate box):
|
⌧
|
No
fee required.
|
|
□
|
Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and
0-11.
|
|
|
(1)
|
Title
of each class of securities to which transaction
applies:
|
|
|
(2)
|
Aggregate
number of securities to which transaction
applies:
|
|
|
(3)
|
Per
unit price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11 (set forth the amount on which the filing fee is
calculated and state how it was
determined):
|
|
|
(4)
|
Proposed
maximum aggregate value of
transaction:
|
|
|
(5)
|
Total
fee paid:
|
|
□
|
Fee
paid previously with preliminary
materials.
|
|
□
|
Check
box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its
filing.
|
|
|
(1)
|
Amount
Previously Paid:
|
|
|
(2)
|
Form,
Schedule or Registration Statement
No.:
|
|
|
(3)
|
Filing
Party:
|
|
|
(4)
|
Date
Filed:
|

NOVABAY
PHARMACEUTICALS, INC.
NOTICE
OF ANNUAL MEETING OF SHAREHOLDERS
TO
BE HELD JUNE 4, 2009
To the
Shareholders of NovaBay Pharmaceuticals, Inc.:
NOTICE IS
HEREBY GIVEN that the 2009 Annual Meeting of Shareholders (the “Annual Meeting”)
of NovaBay Pharmaceuticals, Inc., a California corporation, will be held on
Thursday, June 4, 2009 at 2:00 p.m. Pacific Time at The Marriot Hotel, 5555
Shellmound Street, Emeryville, California 94608 for the following
purposes:
|
|
1.
|
To
elect three Class II directors to hold office for a term of three years or
until their respective successors are elected and
qualified. The nominees for election are Charles Cashion, Alex
McPherson, and Tony Wicks.
|
|
|
2.
|
To
transact any other business which may properly come before the Annual
Meeting or any adjournment or postponement
thereof.
|
Only
shareholders of record at the close of business on April 13, 2009 are entitled
to notice of and to vote at the Annual Meeting and any adjournment or
postponement thereof. A list of shareholders entitled to vote at the
Annual Meeting will be available for inspection at the Annual
Meeting.
|
Important
Notice Regarding the Availability of Proxy Materials for the Shareholder
Meeting to Be Held on Thursday, June 4, 2009.
The proxy statement and annual
report to security holders are available at http://www.edocumentview.com/NBY
|
All
shareholders are cordially invited to attend the meeting in
person. Whether or not you plan to attend, please sign, date and
return the enclosed proxy card in the enclosed postage-paid and addressed
envelope. If your shares are held in “street name” (i.e., your shares
are held in the name of a brokerage firm, bank or other nominee) you should
receive from that institution an instruction form for voting in lieu of a proxy
card. Should you receive more than one proxy card or voting
instruction form because your shares are held in multiple accounts or registered
in different names or addresses, please sign, date and return each proxy card or
voting instruction form to ensure that all of your shares are
voted. You may revoke your proxy at any time prior to the Annual
Meeting. If you attend the Annual Meeting and vote by ballot, your
proxy will be revoked automatically and only your vote at the Annual Meeting
will be counted.
|
By
Order of the Board of Directors,
|
|
|
/s/ Ramin Najafi, Ph.D.
|
|
|
April
16, 2009
|
Ramin
(“Ron”) Najafi, Ph.D.
|
|
Chairman
of the Board, Chief Executive Officer and
President
|
|
YOUR
VOTE IS VERY IMPORTANT REGARDLESS OF THE NUMBER OF SHARES YOU OWN. PLEASE
READ THE ATTACHED PROXY STATEMENT CAREFULLY, COMPLETE, SIGN AND DATE THE
ENCLOSED PROXY CARD AS PROMPTLY AS POSSIBLE AND RETURN IT IN THE ENCLOSED
ENVELOPE.
|
NOVABAY
PHARMACEUTICALS, INC.
5980
Horton Street, Suite 550
Emeryville,
California 94608
PROXY
STATEMENT
These
proxy materials and the enclosed proxy card are being furnished in connection
with the solicitation of proxies by the Board of Directors, or Board, of NovaBay
Pharmaceuticals, Inc., a California corporation, to be voted at the 2009 Annual
Meeting of Shareholders to be held on Thursday, June 4, 2009 (the “Annual
Meeting”) and at any adjournment or postponement of the meeting. The
Annual Meeting will be held at 2:00 p.m. Pacific Time at The Marriot Hotel, 5555
Shellmound Street, Emeryville, California 94608. These proxy
solicitation materials are expected to be mailed on or about May 1, 2009 to all
shareholders entitled to vote at the Annual Meeting.
Purpose
of Meeting
The
specific proposals to be considered and acted upon at the Annual Meeting are
summarized in the accompanying Notice of the Annual Meeting of Shareholders (the
“Notice”) and are described in more detail in this proxy statement.
Voting;
Quorum
The
record date for determining those shareholders who are entitled to notice of,
and to vote at, the Annual Meeting has been fixed as April 13,
2009. Only shareholders of record at the close of business on the
Record Date are entitled to notice of and to vote at the Annual Meeting and any
adjournment or postponement thereof. Each shareholder is entitled to
one vote for each share of our common stock held by such shareholder as of the
Record Date. As of the Record Date 21,659,883 shares of our common
stock were outstanding and no shares of our preferred stock were
outstanding.
The
presence at the Annual Meeting, either in person or by proxy, of holders of a
majority of the outstanding shares of our common stock entitled to vote will
constitute a quorum for the transaction of business at the Annual
Meeting. If a quorum is not present, the Annual Meeting will be
adjourned until a quorum is obtained.
In the
election of directors under Proposal One, the three nominees receiving the
highest number of affirmative votes of our common stock, present or represented
by proxy and entitled to vote at the Annual Meeting, will be
elected.
All votes
will be tabulated by the inspector of election appointed for the Annual Meeting,
who will separately tabulate affirmative and negative votes, abstentions and
broker non-votes (i.e., shares held by a broker or nominee that are represented
at the Annual Meeting, but with respect to which such broker or nominee is not
instructed to vote on a particular proposal and does not have discretionary
voting power). Abstentions and broker non-votes are counted as
present for purposes of determining the presence or absence of a quorum for the
transaction of business. For Proposal One, broker non-votes and votes
marked “withheld” will not be counted towards the tabulation of votes cast on
such proposal presented to the shareholders.
Proxies
Please
use the enclosed proxy card to vote by mail. If your shares are held
in street name, then in lieu of a proxy card you should receive from that
institution an instruction form for voting. Should you receive more
than one proxy card or voting instruction form because your shares are held in
multiple accounts or registered in different names or addresses, please be sure
to complete, sign, date and return each proxy card or voting instruction form to
ensure that all of your shares will be voted. Only proxy cards that
have been signed, dated and timely returned will be counted in the quorum and
voted.
If the
enclosed proxy card is properly signed and returned to us, the shares
represented thereby will be voted at the Annual Meeting in accordance with the
instructions specified thereon. If the proxy does not specify how the
shares represented thereby are to be voted, the proxy will be voted FOR the
election of the directors proposed by the Board under Proposal One.
The
enclosed proxy also grants the proxy holders discretionary authority to vote on
any other business that may properly come before the Annual
Meeting. We have not been notified by any shareholder of his or her
intent to present a shareholder proposal at the Annual Meeting.
If your
shares are held in your name, you may revoke or change your vote at any time
before the Annual Meeting by filing a notice of revocation or another signed
proxy card with a later date with our corporate Secretary at our principal
executive offices at 5980 Horton Street, Suite 550, Emeryville, California
94608. If your shares are held in street name, you should contact the
record holder to obtain instructions if you wish to revoke or change your vote
before the Annual Meeting. If you attend the Annual Meeting and vote
by ballot, any proxy that you submitted previously to vote the same shares will
be revoked automatically and only your vote at the Annual Meeting will be
counted. Simply attending the meeting will not, by itself, revoke
your proxy. Please note, however, that if your shares are held in
street name, your vote in person at the Annual Meeting will not be effective
unless you have obtained and present a proxy issued in your name from the record
holder. Attendance at the Annual Meeting will not, by itself, revoke
a proxy.
Voting
by Telephone or through the Internet
If your
shares are registered in the name of a bank or brokerage firm, you may be
eligible to vote your shares by telephone or through the Internet. A
large number of banks and brokerage firms provide eligible shareholders the
opportunity to vote in this manner. If your bank or brokerage firm
allows for this, your voting form will provide instructions for such alternative
method of voting.
Solicitation
We will
bear the entire cost of proxy solicitation, including the costs of preparing,
assembling, printing and mailing this proxy statement, the proxy card and any
additional solicitation material furnished to the
shareholders. Copies of the solicitation materials will be furnished
to brokerage houses, fiduciaries and custodians holding shares in their names
that are beneficially owned by others so that they may forward this solicitation
material to such beneficial owners. In addition, we may reimburse
such persons for their reasonable expenses in forwarding the solicitation
materials to the beneficial owners. The original solicitation of
proxies by mail may be supplemented by a solicitation by personal contact,
telephone, facsimile, email or any other means by our directors, officers or
employees. No additional compensation will be paid to these
individuals for any such services.
At the
discretion of management, we may retain a professional firm of proxy solicitors
to assist in the solicitation of proxies, although we do not currently expect to
retain such a firm.
2
MATTER
TO BE CONSIDERED AT THE ANNUAL MEETING
PROPOSAL
ONE:
ELECTION
OF DIRECTORS
Our
articles of incorporation provides for a classified board of directors
consisting of three classes of directors, each serving staggered three-year
terms and each as nearly equal in number as possible as determined by our
Board. As a result, a portion of our Board will be elected each
year. Our Board currently consists of eight
persons. Messrs. Cashion and Wicks and Dr. McPherson have been
designated Class II directors whose terms expire at this Annual
Meeting. Mr. Freiman and Drs. Hixson and Najafi have been designated
Class III directors whose terms expire at the 2010 Annual
Meeting. Dr. Dailley and Mr. Tufts have been designated Class I
directors whose terms expire at the 2011 Annual Meeting. The class whose term of
office expires at the Annual Meeting currently consists of three
directors. On the recommendation of the Nominating and Corporate
Governance Committee, our Board selected and approved Charles Cashion, T. Alex
McPherson and Tony Wicks as nominees for election in the class being elected at
the Annual Meeting to serve for a term of three years, expiring at the 2012
Annual Meeting of Shareholders, or until their successors are duly elected and
qualified or until their earlier resignation or removal. Each of the
current nominees was elected to the Board by the Board, and has not previously
been elected by our shareholders. Mr. Cashion was recommended for
initial election to our Board by Paul Freiman; Dr. McPherson was recommended for
initial election to our Board by Jack O’Reilly; and Mr. Wicks was recommended
for initial election to our Board by Dr. Najafi. Each nominee for
election is currently a member of our Board and has agreed to serve if
elected. Management has no reason to believe that any of the nominees
will be unavailable to serve. In the event any of the nominees named
herein is unable to serve or declines to serve at the time of the Annual
Meeting, the persons named in the enclosed proxy will exercise discretionary
authority to vote for substitutes. Unless otherwise instructed, the
proxy holders will vote the proxies received by them FOR the nominees named
below.
Shareholder
Approval
The three
nominees receiving the highest number of affirmative votes of the outstanding
shares of our common stock present or represented by proxy and entitled to vote
at the Annual Meeting shall be elected as directors.
Recommendation
of Our Board of Directors
Our
Board of Directors recommends a vote “FOR” the Class II director nominees listed
below.
Directors
and Nominees
The names
of our directors and nominees, their ages and positions with us as of March 31,
2009, and biographical information about them, are as follows:
|
Name
|
Age
|
Current
Position(s)
|
||
|
Ramin
(“Ron”) Najafi, Ph.D.
|
50
|
Chairman
of the Board, Chief Executive Officer and President
|
||
|
Charles
J. Cashion(1)
|
58
|
Director
|
||
|
Anthony
Dailley, D.D.S.(2)(3)
|
54
|
Director
|
||
|
Paul
E. Freiman(1)(2)
|
74
|
Director
|
||
|
Harry
F. Hixson, Jr.(1)(2)
|
70
|
Director
|
||
|
T.
Alex McPherson, M.D., Ph.D.(3)
|
70
|
Director
|
||
|
Robert
R. Tufts(1)(3)
|
75
|
Director
|
||
|
Tony
D.S. Wicks(2)
|
70
|
Director
|
————————
|
(1)
|
Member
of the Audit Committee.
|
|
(2)
|
Member
of the Compensation Committee.
|
|
(3)
|
Member
of the Nominating and Corporate Governance
Committee.
|
3
Class
II Director Nominees
Charles J.
Cashion has served as a director since November 2005. Mr. Cashion
currently serves as the Senior Vice President, Finance and Chief Financial
Officer of Conatus Pharmaceuticals Inc., a biotechnology start-up company
focused in the areas of inflammation and liver disease, which he co-founded with
other senior management of Idun Pharmaceuticals, Inc. following the sale of Idun
to Pfizer Inc. in July 2005. From 2001 to July 2005, Mr. Cashion was the
Executive Vice President, Chief Financial Officer and Secretary of Idun. Mr.
Cashion’s prior experience also includes serving as the Senior Vice President,
Chief Financial Officer and Secretary of Quidel Corporation, a publicly owned,
medical diagnostics company, and as the Senior Vice President, Finance, Chief
Financial Officer, Secretary, and Treasurer of The Immune Response Corporation,
a publicly owned biopharmaceutical company. Mr. Cashion received his B.S. in
accounting and an M.B.A. in finance from Northern Illinois
University.
T. Alex
McPherson, M.D., Ph.D. has served as a director since July 2006. Dr.
McPherson was President and Chief Executive Officer of Biomira, Inc., a
biotechnology company specializing in the development of products for the
treatment of cancer, from 1991 until his retirement in May 2006. He
is a Fellow of the Australasian, Canadian and American Colleges of Physicians
and is a past President of both the Alberta and Canadian Medical Associations.
Dr. McPherson is currently a Professor Emeritus in the Faculty of Medicine of
the University of Alberta, and was Deputy Minister of the Alberta Ministry of
Hospitals and Medical Care, and was Deputy Commissioner and Executive Director
of the Premier’s Commission on Future Health Care for Albertans (The Rainbow
Report). He also serves on the board of directors of Carrington
Laboratories, Inc. Dr. McPherson received his M.D. in medicine from
the University of Alberta and his Ph.D. from the University of
Melbourne.
Tony D.S. Wicks
has served as a director since May 2002. He also served as a director of
NovaCal Pharmaceuticals LLC (“NovaCal LLC”) from March 2001 to May 2002. Since
1995, Mr. Wicks has been pursuing private investments, venture work and
participating in property investments. Mr. Wicks received his H.N.C. in
electrical engineering from Essex Polytechnic.
Directors
Whose Terms Continue
Class
III Directors — Terms Expiring at the 2010 Annual Meeting
Paul E. Freiman
has served as a director since May 2002. He also served as a director of
NovaCal LLC from May 2001 to May 2002. Since May 1997, Mr. Freiman has been the
President and Chief Executive Officer of Neurobiological Technologies, Inc., a
biotechnology company focused on acquiring and developing central nervous system
related drug candidates. He has also served as a member of the board of
directors of Neurobiological Technologies since April 1997. Mr. Freiman’s prior
experience includes serving as the former Chairman and Chief Executive Officer
of Syntex Corporation, which was sold to The Roche Group for $5.3 billion during
his tenure. Mr. Freiman currently serves as Chairman of Penwest Pharmaceutical
Co., and serves on the boards of Calypte Biomedical Corporation and NeoPharm,
Inc. Mr. Freiman received a B.S. degree in pharmacy from Fordham University and
an honorary doctorate from the Arnold & Marie Schwartz College of
Pharmacy.
Harry F. Hixson,
Jr., Ph.D. has served as a director of
NovaBay Pharmaceuticals, Inc. since January 2009. He currently serves
as Chairman of the Board of Sequenom Inc., a public genetics and molecular
diagnostic company. He is also a member of the board of directors of Infinity
Pharmaceuticals, Inc., a public cancer drug discovery and development
company. Dr. Hixson has also served as a director of Arena
Pharmaceuticals, Inc. since 2004, and currently serves as the Chairman of
BrainCells, Inc., a privately held biopharmaceutical company focused on central
nervous system drug development. Dr. Hixson has served as Chairman of BrainCells
since December 2003 and was Chief Executive Officer from July 2004 until
September 2005. Dr. Hixson received his Ph.D. in Physical
Biochemistry from Purdue University and an MBA from the University of Chicago.
He also received an Honorary Doctor of Science degree from Purdue
University.
Ramin (“Ron”)
Najafi, Ph.D. has served as our Chairman of the Board and President since
July 2002, and as our Chief Executive Officer since November 2004. Prior to
joining us, from January 2000 to June 2002, Dr. Najafi served in various
management positions with NovaCal LLC, including as Chairman of the Board from
January 2000 to June 2002, as President and Chief Scientific Officer from
February 2002 to June 2002, and as Chief Executive Officer from January 2000 to
February 2002. Dr. Najafi received a B.S. and M.S. degree in Chemistry from the
University of San Francisco and a Ph.D. in Organic Chemistry from the University
of California at Davis.
4
Class
I Director Nominees – Terms Expiring at the 2011 Annual Meeting
Anthony Dailley,
D.D.S. has served as a director since May 2002. Dr. Dailley is one of our
founders and has been involved in a number of start-up companies, including
serving as a director of NovaCal LLC from January 2000 to May 2002. We acquired
all of the assets of NovaCal LLC in July 2002. Dr. Dailley currently serves as
the President of Breathcare, a specialty dental practice which he founded in
2000. From 1995 to 2000, he was the Treasurer and a member of the board of
directors of Indicator Technologies, Inc., a medical device company in
California. Dr. Dailley received his B.S. in cell and molecular biology from San
Francisco State University and his dental degree from the University of the
Pacific School of Dentistry in San Francisco.
Robert R. Tufts
has served as a director since May 2002. He also served as a director of
NovaCal LLC from February 2001 to May 2002. Mr. Tufts is a founding law partner
of Tufts Stephenson & Kasper, LLP, which was formed in April 1999, and was
formerly a partner with Jackson Tufts Cole and Black, LLP for over 35 years. He
specializes in corporate representation for start-up and emerging businesses,
business financings, mergers and acquisitions, and in corporate taxation. Mr.
Tufts received his B.A. in history from New York University and received his law
degree from Harvard Law School.
Family
Relationships
There are
no family relationships among any of our directors, executive officers or
director nominees.
CORPORATE
GOVERNANCE
Code
of Ethics and Business Conduct
Our Board
has adopted a Code of Ethics and Business Conduct which applies to all
directors, officers (including our principal executive officer, principal
financial officer, principal accounting officer or controller, or persons
performing similar functions) and employees. The full text of our
Code of Ethics and Business Conduct is available on the Corporate Governance
section of our website at www.novabaypharma.com. We
intend to disclose future amendments to certain provisions of the Code of Ethics
and Business Conduct, and any waivers of provisions of the Code of Ethics
required to be disclosed under the rules of the Securities and Exchange
Commission (“SEC”), at the same location on our website.
Director
Independence
The Board
has determined that Messrs. Cashion, Freiman, McPherson, Tufts and Wicks and
Drs. Dailley and Hixson, each satisfies the requirements for “independence” as
defined in the NYSE Amex Company Guide.
Board
Committees and Meetings
Our Board
has an Audit Committee, a Compensation Committee, and a Nominating and Corporate
Governance Committee. The Audit Committee, the Compensation
Committee, and the Nominating and Corporate Governance Committee each has a
written charter that is reviewed annually and revised as
appropriate. A copy of each committee’s charter is available on the
Corporate Governance section of our website at www.novabaypharma.com.
During
the year ended December 31, 2008, the Board and the various committees of the
Board held the following number of meetings: Board of
Directors—eight; Audit Committee—four; Compensation Committee—seven; and
Nominating and Corporate Governance Committee—seven. During 2008, no
director attended fewer than 75% of the aggregate of the total number of
meetings of the Board and the total number of meetings of any committees of the
Board held while he was serving on the Board or such committee.
5
Audit
Committee. Our 2008 Audit Committee consisted of Messrs.
Cashion, Freiman and Wicks. Mr. Cashion is the Chair of the Audit
Committee. Our Board has determined that each member of the Audit
Committee is independent, as defined in the NYSE Amex Company Guide and Rule
10A-3 under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”). Mr. Cashion qualifies as an “audit committee financial expert”
as that term is defined in the rules and regulations established by the
SEC. The functions of this committee include:
|
|
·
|
meeting
with our management periodically to consider the adequacy of our internal
controls and the objectivity of our financial
reporting;
|
|
|
·
|
meeting
with our independent auditors and with internal financial personnel
regarding these matters;
|
|
|
·
|
pre-approving
audit and non-audit services to be rendered by our independent
auditors;
|
|
|
·
|
engaging
and determining the compensation of our independent auditors and oversight
of the work of our independent
auditors;
|
|
|
·
|
reviewing
our financial statements and periodic reports and discussing the
statements and reports with our management and independent auditors,
including any significant adjustments, management judgments and estimates,
new accounting policies and disagreements with
management;
|
|
|
·
|
establishing
procedures for the receipt, retention and treatment of complaints received
by us regarding accounting, internal accounting controls and auditing
matters;
|
|
|
·
|
reviewing
our financing plans and reporting recommendations to our full Board for
approval and to authorize action;
and
|
|
|
·
|
administering
and discussing with management and our independent auditors our Code of
Ethics.
|
Both our
independent auditors and internal financial personnel regularly meet privately
with the Audit Committee and have unrestricted access to this
committee.
We have
reconstituted the membership of our Committees and the 2009 Audit Committee
consists of Messrs. Cashion, Freiman, and Tufts and Dr. Hixson effective January
14, 2009.
Compensation
Committee. Our 2008 Compensation Committee consisted of Messrs. Wicks,
Freiman, and Tufts and Drs. Dailley and McPherson. Mr. Wicks is the
Chair of our Compensation Committee. Our Board has determined that
each member of the Compensation Committee is independent, as defined in the NYSE
Amex Company Guide. The functions of this committee
include:
|
|
·
|
reviewing
and, as it deems appropriate, recommending to our Board, policies,
practices and procedures relating to the compensation of our directors,
officers, and other managerial employees and the establishment and
administration of our employee benefit
plans;
|
|
|
·
|
exercising
authority under our employee benefit
plans;
|
|
|
·
|
reviewing
and approving executive officer and director indemnification and insurance
matters; and
|
|
|
·
|
advising
and consulting with our officers regarding managerial personnel and
development.
|
The
Compensation Committee may delegate its authority to act to subcommittees of the
Compensation Committee, as set forth in its charter, but has not done so
historically.
6
Decisions
regarding executive compensation are ultimately determined by the Compensation
Committee, which reviews a number of factors in its decisions, including market information about
the compensation of executive officers at similar-sized biotechnology companies
within our geographic region, or peer group companies, and
recommendations from our Chief Executive Officer and Chief Financial
Officer. Additionally, the Compensation Committee subscribes to the Radford Life
Science Compensation Survey, or Compensation Survey, from which we collect
data for base salary, target annual bonuses and equity compensation for various
positions at our peer group companies. The market data is used as
a guide, against which the Compensation Committee evaluates the compensation of
each of the named executive officers in light of the executive's scope of
responsibility, expertise and business knowledge. Consultants
from Radford are available to the Compensation Committee to help us review the
Compensation Survey data and benchmarks for our peer group
companies. Radford Life Science is engaged directly by the
Compensation Committee. The Chief Executive Officer and Chief
Financial Officer attend all meetings of the Compensation Committee except where
their respective compensation packages are being
discussed. This process allows the
Compensation Committee to set compensation at levels it believes are appropriate
to retain and motivate our named executive officers.
In 2008,
the Compensation Committee used market benchmarks to determine its
recommendations for executive compensation. The Compensation
Committee reviewed market reference data to evaluate the competitiveness of our
executive officers’ compensation and to determine whether the total compensation
paid to each of our named executive officers was reasonable in the aggregate. We
compared the salaries of our executives as of December 31, 2007 with data of
companies in the life sciences industry with 50 employees or less.
Future
decisions regarding executive compensation will continue to be the
responsibility of our Compensation Committee.
As of
January 14, 2009, our Compensation consists of Messrs. Freiman and Wicks and
Drs. Dailley and Hixson.
Nominating and
Corporate Governance Committee. Our 2008 Nominating and
Corporate Governance Committee consisted of Messrs. Freiman, Tufts and Wicks and
Dr. McPherson. Dr. McPherson is the Chair of our Nominating and
Corporate Governance Committee. Our Board has determined that each
member of the Nominating and Corporate Governance Committee is independent, as
defined in the NYSE Amex Company Guide. The functions of this
committee include:
|
|
·
|
identifying
qualified candidates to become members of our
Board;
|
|
|
·
|
selecting
nominees for election of directors at the next annual meeting of
shareholders (or special meeting of shareholders at which directors are to
be elected);
|
|
|
·
|
selecting
candidates to fill vacancies on our
Board;
|
|
|
·
|
developing
and recommending to our Board our corporate governance guidelines;
and
|
|
|
·
|
overseeing
the evaluation of our Board.
|
In
connection with their recommendations regarding the size and composition of the
Board, the Nominating and Corporate Governance Committee reviews the appropriate
qualities and skills required of directors in the context of the then current
make-up of the Board. This includes an assessment of each candidate’s
independence, personal and professional integrity, financial literacy or other
professional or business experience relevant to an understanding of our
business, ability to think and act independently and with sound judgment, and
ability to serve our and its shareholders’ long-term interests. These
factors, and others as considered useful by the Nominating and Corporate
Governance Committee, are reviewed in the context of an assessment of the
perceived needs of the Board at a particular point in time. As a
result, the priorities and emphasis of the Nominating and Corporate Governance
Committee and of the Board may change from time to time to take into account
changes in business and other trends, and the portfolio of skills and experience
of current and prospective directors. The Nominating and Corporate
Governance Committee leads the search for and selects, or recommends that the
Board select candidates for election to the Board. Consideration of
new director candidates typically involves a series of committee discussions,
review of information concerning candidates and interviews with selected
candidates. Candidates for nomination to our Board typically have
been suggested by other members of the Board or by our executive
officers. From time to time, the Nominating and Corporate Governance
Committee may engage the services of a third-party search firm to identify
director candidates.
7
The
Nominating and Corporate Governance Committee will consider candidates for
directors recommended by our shareholders who meet the eligibility requirements
for submitting shareholder proposals for inclusion in our next proxy
statement. This committee will evaluate such recommendations applying
its regular nominee criteria. Eligible shareholders wishing to
recommend a nominee must submit such recommendation in writing to the Chair,
Nominating and Corporate Governance Committee, care of the corporate Secretary,
by the deadline for shareholder proposals set forth in the prior year’s proxy
statement, specifying the following information: (i) the
shareholder’s intent to nominate one or more persons for election as director of
the corporation, the name of each such nominee proposed by the shareholder
giving the notice, and the reason for making such nomination at the annual
meeting, (ii) name and address, as they appear on the corporation’s books, of
the shareholder proposing such nomination and the beneficial owner, if any, on
whose behalf the nomination is proposed, (iii) the class and number of shares of
the corporation that are owned beneficially and of record by the shareholder
proposing such nomination and the beneficial owner, if any, on whose behalf the
nomination is proposed, (iv) any material interest of such shareholder proposing
such nomination and the beneficial owner, if any, on whose behalf the proposal
is made, (v) a description of all arrangements or understandings between or
among any of (A) the shareholder giving the notice, (B) each nominee and (C) any
other person or persons (naming such person or persons) pursuant to which the
nomination or nominations are to be made by the shareholder giving the notice,
(vi) such information as the Board or the Nominating and Corporate Governance
Committee, or similar committee appointed by the Board, may require pursuant to
resolutions of the Board or such committee’s charter, (vii) such other
information regarding each nominee proposed by the shareholder giving the notice
as would be required to be included in a proxy statement filed in accordance
with proxy rules of the SEC had the nominee been nominated, or intended to be
nominated, by the Board and (viii) the signed consent of each nominee proposed
by the shareholder giving the notice to serve as a director of the corporation
if so elected.
No
candidates for director nominations were submitted to the Nominating and
Corporate Governance Committee by any shareholder in connection with the
election of directors at the Annual Meeting. Each of the director
nominees standing for election at this Annual Meeting is a current director of
NovaBay.
Effective
January 14, 2009, our Nominating and Corporate Governance Committee consists of
Drs. Dailley and McPherson and Mr. Tufts.
Annual
Meeting Attendance
We do not
have a formal policy regarding attendance by members of our Board at annual
meetings of shareholders; however, directors are encouraged to attend all such
meetings.
Shareholder
Communications to the Board
Our Board
has implemented a process by which shareholders may send written communications
directly to the attention of the Board, any committee of the Board or any
individual Board member, care of our Chief Executive Officer (“CEO”), Ron
Najafi, at 5980 Horton Street, Suite 550, Emeryville, California
94608. The name of any specific intended Board recipient should be
noted in the communication. Our CEO will be primarily responsible for
collecting, organizing and monitoring communications from shareholders and,
where appropriate depending on the facts and circumstances outlined in the
communication, providing copies of such communications to the intended
recipients. Communications will be forwarded to directors if they
relate to appropriate and important substantive corporate or Board
matters. Communications that are of a commercial or frivolous nature
or otherwise inappropriate for the Board’s consideration will not be forwarded
to the Board.
8
FEES
PAID TO INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Principal
Accountant Fees
The
following table sets forth the fees billed to us for the fiscal years ended
December 31, 2007 and 2008 by Davidson & Company LLP (“Davidson”), our
independent registered public accounting firm for such years:
|
2008
|
2007
|
|||||||
|
Audit
Fees
|
$ | 109,864 | $ | 115,486 | ||||
|
Audit-Related
Fees
|
― | ― | ||||||
|
Tax
Fees
|
― | ― | ||||||
|
All
Other Fees
|
― | ― | ||||||
|
Total
Fees
|
$ | 109,864 | $ | 115,486 | ||||
Audit
Fees. Audit fees consisted of fees billed by Davidson for
professional services rendered in connection with the audit and quarterly
reviews of our consolidated financial statements. Such fees included
fees associated with the review of the registration statement on Form
S-8.
Audit-Related
Fees. There were no fees billed by Davidson for audit-related
services in 2007 or 2008.
Tax
Fees. There were no fees billed by Davidson for tax services
in 2007 or 2008.
All Other
Fees. There were no fees billed by Davidson for other services
in 2007 or 2008.
Policy
on Audit Committee Pre-Approval of Audit and Permissible Non-Audit
Services
All
engagements for services by Davidson or other independent registered public
accountants are subject to prior approval by the Audit Committee; however, de
minimis non-audit services may instead be approved in accordance with applicable
SEC rules. The Audit Committee approved all services provided by
Davidson for the fiscal years ended December 31, 2007 and 2008.
AUDIT
COMMITTEE REPORT
The
following is the report of the Audit Committee with respect to the audited
consolidated financial statements of NovaBay Pharmaceuticals, Inc. (the
“Company”) for the fiscal year ended December 31, 2008 included in the Annual
Report on Form 10-K for that year.
The Audit
Committee has reviewed and discussed the audited financial statements of the
Company for the fiscal year ended December 31, 2008 with the Company’s
management. The Audit Committee has discussed with the Company’s
independent registered public accounting firm, Davidson & Company LLP, the
matters required to be discussed by Statement on Auditing Standards No. 114,
Communication with Audit
Committees.
The Audit
Committee has also received the written disclosures and the letter from Davidson
& Company LLP required by Ethics and Independence Rule 3526, Communications with Audit Committees
Concerning Independence, and has discussed with Davidson & Company
LLP the independence of Davidson & Company LLP.
Based on
the review and discussions referred to above in this report, the Audit Committee
recommended to the Company’s Board of Directors that the audited financial
statements be included in the Company’s Annual Report on Form 10-K for the year
ended December 31, 2008 for filing with the Securities and Exchange
Commission.
|
Submitted
by the Audit Committee
|
|
|
of
the Board of Directors:
|
|
|
Charles
J. Cashion
|
|
|
Paul
E. Freiman
|
|
|
Tony
D.S. Wicks
|
9
EXECUTIVE
COMPENSATION AND OTHER INFORMATION
Executive
Officers
The table
below sets forth certain information regarding our executive officers as of
March 31, 2009.
|
Name
|
Age
|
Current
Position(s)
|
||
|
Ramin
(“Ron”) Najafi, Ph.D.
|
50
|
Chairman
of the Board, Chief Executive Officer and President
|
||
|
Thomas
J. Paulson
|
62
|
Chief
Financial Officer and Treasurer
|
||
|
Behzad
Khosrovi, Ph.D.
|
65
|
Vice
President, Research and
Development
|
The
following is certain biographical information regarding our executive
officers. The biography of Dr. Najafi appears earlier in this proxy
statement. See “Proposal One: Election of
Directors.”
Thomas J.
Paulson has served as our Chief Financial Officer and Treasurer since
January 2008. Prior to joining us, Mr. Paulson was a partner at Tatum
LLC, an executive services and consulting firm which he joined in April 2007,
and the President and Chief Executive Officer of The Paulson Group, a management
consulting company whose clients included high-technology and biotechnology
companies, which he founded in February 2006. Immediately prior to
forming the consulting firm, Mr. Paulson was Vice President-Finance, Chief
Financial Officer and Secretary of Avigen, Inc., a publicly traded
biopharmaceutical company focused on unique and small molecule therapeutics and
biologics, from 1996 to January 2006. Mr. Paulson received a B.A. in Business
Administration from Loyola University in Chicago and an M.B.A. from the
University of Chicago.
Behzad Khosrovi,
Ph.D. has served as our Vice President, Research & Development since
November 2003. Dr. Khosrovi received an M.A. in natural science from
Cambridge University and a Ph.D. in applied microbiology and biochemical
engineering from Manchester University.
Summary
Compensation Table
The
following table shows information regarding the compensation earned during the
fiscal years ended December 31, 2006, 2007 and 2008 by (i) our Chief
Executive Officer, (ii) our Vice President, for Research and Development, and
(iii) our Chief Financial Officer who were serving as executive officers in
2008. The officers listed below are collectively referred to as the
“Named Executive Officers” in this proxy statement.
|
Name
|
Fiscal
Year
|
Salary
|
Bonus
|
Option Awards(1)
|
All
Other Compensation(2)
|
Total
|
||||||||||||||||
|
Ramin
(“Ron”) Najafi, Ph.D.
|
2008
|
$ | 356,000 | — | $ | 93,140 | $ | 17,800 | $ | 466,940 | ||||||||||||
|
Chairman,
CEO and President
|
2007
|
$ | 319,999 | $ | 135,680 | $ | 3,017 | $ | 616 | $ | 459,312 | |||||||||||
|
Thomas
J. Paulson,
|
2008
|
$ | 250,000 | — | $ | 103,456 | — | $ | 353,456 | |||||||||||||
|
CFO
(3)
|
|
|||||||||||||||||||||
|
Behzad
Khosrovi, Ph.D.
|
2008
|
$ | 238,000 | — | $ | 29,558 | $ | 5,950 | $ | 273,508 | ||||||||||||
|
VP,
Research and Development
|
2007
|
$ | 231,249 | $ | 60,241 | $ | 905 | $ | 8,820 | $ | 301,215 | |||||||||||
|
(1)
|
Represents
the expense recognized by us for the applicable fiscal year for stock
options, determined pursuant to SFAS 123(R) utilizing assumptions
discussed in Note 10 to our consolidated financial statements in our
annual report for the year ended December 31, 2008 (the “Annual Report”)
regarding assumptions underlying valuation of equity
awards. See also our discussion of share-based compensation
under “Management’s Discussion and Analysis of Financial Condition and
Results of Operations—Critical Accounting Policies and Estimates” in the
Annual Report.
|
|
(2)
|
These
amounts represent cash compensation for accrued and unused vacation leave
entitlements.
|
|
(3)
|
Mr.
Paulson was not employed by us prior to fiscal year
2008.
|
10
In 2008,
our Named Executive Officers were awarded stock options under our 2007 Omnibus
Incentive Plan at an exercise price per share equal to the closing sales price
of our common stock on the American Stock Exchange (now NYSE Amex) on the date
of the grant. These options are not exercisable until vested, and
vest as to 25% of the shares underlying the option on the first anniversary of
the grant date, with the remainder vesting in 12 equal installments thereafter
upon the completion of three (3) months beginning September 5,
2009.
Given the
business environment, in 2008, the Compensation Committee, with the support of
management, determined not to grant bonuses to our executive
officers. In 2007, bonuses were awarded to our executive officers
primarily based on their contributions to achieving specific development and
other business goals. The bonuses paid to Named Executive Officers for 2007
ranged from 18% to 42% of their base salaries and totaled
$195,921. See also our discussion of Named Executive Officer
compensation under “Outstanding Equity Awards at Fiscal Year-End” and
“Employment Contracts and Termination of Employment and Change of Control
Arrangements” below.
Outstanding
Equity Awards at Fiscal Year-End
The
following table presents the outstanding equity awards held by each of the Named
Executive Officers as of December 31, 2008. Stock options were
granted pursuant to our 2002 Stock Option Plan (“2002 Plan”) and 2005 Stock
Option Plan (“2005 Plan”) prior to our initial public offering in October 2007
and pursuant to our 2007 Omnibus Incentive Plan thereafter. All
options granted under our 2002 Plan and 2005 Plan were immediately exercisable
and, except as otherwise noted below, vest as to 25% of the shares underlying
the grant on the first anniversary of the grant date, with the remainder vesting
in 12 equal quarterly installments thereafter over the three year period
following the first anniversary of the date of grant. The options
granted under our 2007 Plan are not exercisable until they have vested, and vest
as to 25% of the shares underlying the option on the first anniversary of the
grant date, with the remainder vesting in 12 equal installments thereafter upon
the completion of three (3) months beginning the first anniversary of the grant
date.
|
Option
Awards
|
|||||||||||||
|
Name
|
Number
of Securities Underlying Unexercised Options (#)
Exercisable
|
Number
of Securities Underlying Unexercised Options (#)
Unexercisable
|
Option
Exercise Price ($)
|
Option
Expiration Date
|
|||||||||
|
Ramin
(“Ron”) Najafi, Ph.D.
|
39,062 | (2) | 85,938 | (2) | $ | 3.56 |
12/13/17
|
||||||
|
Chairman,
CEO and President
|
65,000 | (5) | $ | 1.95 |
09/05/18
|
||||||||
|
Thomas
J. Paulson
|
― | 200,000 | (3) | $ | 3.80 |
01/14/18
|
|||||||
|
Chief
Financial Officer and Treasurer
|
― | 44,400 | (6) | $ | 1.95 |
09/05/18
|
|||||||
|
Behzad
Khosrovi, Ph.D.
|
200,000 | (1) | ― | 0.30 |
01/29/14
|
||||||||
|
VP,
Research and Development
|
11,718 | (4) | 25,782 | (4) | 3.56 |
12/13/17
|
|||||||
| 35,400 | (7) | $ | 1.95 |
09/05/18
|
|||||||||
————————
|
(1)
|
In
December 2003, Dr. Khosrovi was granted an option to purchase an aggregate
of 200,000 shares of our common stock. 25,000 shares subject to such
option were fully vested as of the date of grant. The remaining shares
were to vest upon reaching certain company milestones, including full
vesting upon the completion of our initial public offering. The
option was fully vested as of December 31,
2008.
|
11
|
(2)
|
In
December 2007, Dr. Najafi was granted an option to purchase an aggregate
of 125,000 shares of our common stock. The option vests as to
25% of the shares underlying the option on the first anniversary of the
grant date, with the remainder vesting in 12 equal installments thereafter
at the end of each calendar quarter beginning December 31,
2008.
|
|
(3)
|
In
January 2008, Mr. Paulson was granted an option to purchase 200,000 shares
of our common stock. The option vests as to 25% of the shares
underlying the option on the first anniversary of the grant date, with the
remainder vesting in 12 equal installments thereafter upon each
three-month anniversary of the grant date of January 14,
2009.
|
|
(4)
|
In
December 2007, Dr. Khosrovi was granted an option to purchase an aggregate
of 37,500 shares of our common stock. The option vests as to
25% of the shares underlying the option on the first anniversary of the
grant date, with the remainder vesting in 12 equal installments thereafter
at the end of each calendar quarter beginning December 31,
2008.
|
|
(5)
|
In
September 2008, Dr. Najafi was granted an option to purchase 65,000 shares
of our common stock. The option vests as to 25% of the shares
underlying the option on the first anniversary of the grant date, with the
remainder vesting in 12 equal installments thereafter upon each
three-month anniversary of the grant date of September 5,
2009.
|
|
(6)
|
In
September 2008, Mr. Paulson was granted an option to purchase 44,400
shares each of our common stock. The option vests as to 25% of
the shares underlying the option on the first anniversary of the grant
date, with the remainder vesting in 12 equal installments thereafter upon
each three-month anniversary of the grant date of September 5,
2009.
|
|
(7)
|
In
September 2008, Mr. Khosrovi was granted an option to purchase 35,400
shares each of our common stock. The option vests as to 25% of
the shares underlying the option on the first anniversary of the grant
date, with the remainder vesting in 12 equal installments thereafter upon
each three-month anniversary of the grant date of September 5,
2009.
|
Employment
Contracts and Termination of Employment and Change of Control
Arrangements
We
entered into a four-year employment agreement, effective as of January 2007,
with each of Mr. Khosrovi and Dr. Najafi. Pursuant to the terms of these
agreements, the annual salaries for these officers will be at least $208,125 for
Mr. Khosrovi and $320,000 for Dr. Najafi, subject to periodic increase at the
discretion of our Board. Each of the officers are also entitled to
five weeks of vacation and to participate in all of our benefit programs that
are generally available to similar, high level executives, as well as any
additional benefits that may be approved by the Board. In the event
Mr. Khosrovi’s employment is terminated for any reason other than for cause, we
will be required to pay him an amount equal to 12 months salary at his salary
rate as then in effect plus an amount equal to the bonus that was paid to such
officer for his services during the previous calendar year. In the
event Dr. Najafi’s employment is terminated for any reason other than for cause,
we will be required to pay him an amount equal to 18 months salary at his salary
rate as then in effect plus an amount equal to the bonus that was paid to such
officer for his services during the previous calendar year. Such
amounts will be paid in two equal installments, the first on the first day of
the seventh month after the date of termination and the second installment on
the first day of the thirteenth month after the date of termination. In the
event that any either officer is terminated for cause, then we will be required
to pay to the applicable officer a lump sum of $15,000 within 60 days of such
officer’s termination.
We also
entered into a four-year employment agreement with Mr. Paulson effective January
2008. Pursuant to the terms of the agreement, the annual salary for
Mr. Paulson will be $250,000, subject to periodic adjustment at the discretion
of our Board, provided that his then current annual salary cannot be reduced
without his consent. Mr. Paulson is also entitled to five weeks of
vacation and to participate in all of our benefit programs that are generally
available to similar, high level executives, as well as any additional benefits
that may be approved by the Board. Although Mr. Paulson will be
employed on an at-will basis, in the event that his employment is terminated for
any reason other than for cause, we will be required to pay him an amount equal
to up to one year’s salary at his salary rate as then in effect plus an amount
equal to the bonus which was paid to him for his services during the previous
calendar year. Such amounts will be paid within approximately six to 12 months,
depending on the amounts to be paid. In the event that Mr. Paulson is terminated
for cause after at least 12 months of employment with us, we will be required to
pay him a lump sum of $15,000 within 60 days of the termination.
12
Mr.
Paulson was granted a stock option in January 2008 to purchase up to 200,000
shares of our common stock at an exercise price of $3.80 per
share. The option is immediately exercisable prior to vesting, and
vests over four years, subject to his continued employment, with 25% of the
option vesting on the one year anniversary of his hire date and the remainder
vesting in equal quarterly installments over the following 36
months. Upon a change in control of NovaBay, all unvested shares
subject to the option will immediately vest in full.
Director
Compensation
The
compensation and benefits for services as a member of our Board is determined by
our Board of Directors. Directors employed by us are not compensated
for service on the Board or any committee of the Board; however, we reimburse
all directors for any out-of-pocket expenses incurred in connection with
attending meetings of our Board and committees of our Board.
In March
2007, our Board approved a director compensation plan (the “Directors Plan”),
which was approved by our shareholders in April 2007 and became effective upon
the completion of our initial public offering in October 2007. Under
the Directors Plan, our non-employee directors receive cash and shares of our
common stock for each meeting of the Board and for each meeting of a committee
of the Board that such director attends, up to the maximums set forth below. The
number of shares of common stock actually received for any meeting is based on
the market value of the stock on the date of the meeting, subject to a minimum
per share price. The chairpersons of the Audit Committee, the Compensation
Committee and the Nominating and Corporate Governance Committee receive higher
compensation than other members of such committees for attending committee
meetings. The Directors Plan provides for non-employee
directors compensation until December 31, 2009.
The table
below sets forth the amounts received or to be received pursuant to the
Directors Plan by the non-employee directors for attending meetings of the Board
and of Board committees for the years 2008 and 2009.
|
Year
|
Board
Meetings
|
Chairperson
of Committee for
Committee
Meetings
|
All
Other Members for
Committee
Meetings
|
|||
|
2008
|
$1,800
in cash and $2,700 in common stock per meeting (maximum of $10,800 in cash
and $16,200 in stock for the year)
|
$800
in cash and $1,200 in common stock per meeting (maximum of $4,000 in cash
and $6,000 in stock for the year)
|
$400
in cash and $600 in common stock per meeting (maximum of $2,000 in cash
and $3,000 in stock for the year)
|
|||
|
2009
|
· Annual
retainer of $6,000 in cash and $9,000 in common stock payable on January
15, 2009
· $1,800 in
cash and $2,700 in common stock per meeting (maximum of $10,800 in cash
and $16,200 in stock for the year)
|
$800
in cash and $1,200 in common stock per meeting (maximum of $4,000 in cash
and $6,000 in stock for the year)
|
$400
in cash and $600 in common stock per meeting (maximum of $2,000 in cash
and $3,000 in stock for the
year)
|
Non-employee
directors are also eligible to participate in our equity incentive plans and may
be granted awards under such plans, at the discretion of our Board. Under the
Directors Plan, the Board may grant stock options to newly elected non-employee
directors upon their first appointment or election to the Board. If granted,
such options will have an exercise price per share equal to the fair market
value of our common stock on the date of grant and will vest one-third at the
end of the first year and one-twelfth at the end of each calendar quarter after
the end of the first year, subject to the director’s continuing service on our
Board. Options that have been previously granted to the non-employee directors
will continue to vest in accordance with their respective terms.
Dr.
Hixson, the new Board member was granted a stock option in January 2009 to
purchase up to 52,000 shares of our common stock at an exercise price of $1.33
per share. The option vests over four years, subject to his continued
service to NovaBay as a Board member, with 25% of the option vesting on the one
year anniversary of his hire date and the remainder vesting in equal quarterly
installments over the following 36 months. Upon a change in control
of NovaBay, all unvested shares subject to the option will immediately vest in
full.
13
The
compensation received during 2008 by each director who is not a Named Executive
Officer is set forth below.
|
Name
|
Fees
Earned or Paid in Cash ($)
|
Stock
Awards ($)(1)
|
Option
Awards ($)(2)
|
Total
($)
|
||||||||||||
|
Charles
J. Cashion
|
$ | 14,800 | $ | 22,008 | 11,014 | 47,822 | ||||||||||
|
Anthony
Dailley
|
12,800 | 19,200 | – | 32,000 | ||||||||||||
|
Paul
E. Freiman
|
12,800 | 19,227 | – | 32,027 | ||||||||||||
|
Harry
F. Hixson, Jr.
|
– | – | – | – | ||||||||||||
|
T.
Alex McPherson
|
14,800 | 22,380 | 11,043 | 48,223 | ||||||||||||
|
Robert
R. Tufts
|
14,800 | 19,200 | – | 34,000 | ||||||||||||
|
Tony
D.S. Wicks
|
14,800 | 22,200 | – | 37,000 | ||||||||||||
|
(1)
|
All
stock awards were fully vested upon grant. No options were
granted to our non-employee directors in
2008.
|
|
(2)
|
The
amounts listed represent the expense recognized by us for fiscal year 2008
for the equity awards granted, determined pursuant to SFAS 123(R)
utilizing assumptions discussed in Note 10 to our consolidated financial
statements in our Annual Report. See also our discussion of
share-based compensation under “Management’s Discussion and Analysis of
Financial Condition and Results of Operations—Critical Accounting Policies
and Estimates” in the Annual
Report.
|
SECURITY
OWNERSHIP OF
CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT
The
following table indicates information as of March 31, 2009 regarding the
ownership of our common stock by:
|
|
·
|
each
person who is known by us to own more than 5% of our shares of common
stock;
|
|
|
·
|
each
Named Executive Officer;
|
|
|
·
|
each
of our directors; and
|
|
|
·
|
all
of our directors and executive officers as a
group.
|
The
number of shares beneficially owned and the percentage of shares beneficially
owned are based on 21,649,204 shares of common stock outstanding as of March 31,
2009. Beneficial ownership is determined in accordance with the rules
and regulations of the Securities and Exchange Commission. Shares
subject to options that are exercisable within 60 days following March 31, 2009
are deemed to be outstanding and beneficially owned by the optionee for the
purpose of computing share and percentage ownership of that optionee, but are
not deemed to be outstanding for the purpose of computing the percentage
ownership of any other person. Except as indicated in the footnotes
to this table, and as affected by applicable community property laws, all
persons listed have sole voting and investment power for all shares shown as
beneficially owned by them.
14
|
Name
and Address of Beneficial Owners(1)
|
Number
of
Shares
|
Percent
of
Class
|
||||||
|
Named Executive Officers and
Directors
|
||||||||
|
Ramin
(“Ron”) Najafi, Ph.D.(2)
|
3,174,575 | 14.6 | % | |||||
|
Thomas
J. Paulson (3)
|
66,500 | * | ||||||
|
Behzad
Khosrovi, Ph.D.(4)
|
350,062 | 1.6 | ||||||
|
Harry
F. Hixson, Jr.(5)
|
12,651 | |||||||
|
Charles
J. Cashion(6)
|
105,144 | * | ||||||
|
Anthony
Dailley, DDS(7)
|
364,655 | 1.7 | ||||||
|
Paul
E. Freiman(8)
|
186,908 | * | ||||||
|
T.
Alex McPherson, MD, Ph.D.(9)
|
104,008 | * | ||||||
|
Robert
R. Tufts(10)
|
371,719 | 1.7 | ||||||
|
Tony
D.S. Wicks(11)
|
260,854 | 1.2 | ||||||
|
All
directors and executive officers as a group (10
persons)(12)
|
4,997,067 | 22.1 | % | |||||
————————
|
*
|
Less
than 1%.
|
|
(1)
|
The
address for each of the persons listed is c/o NovaBay Pharmaceuticals,
Inc., 5980 Horton Street, Suite 550, Emeryville, California
94608.
|
|
(2)
|
Includes
(i) 3,117,500 shares of common stock held by the Najafi Family Trust dated
September 13, 2006, of which Dr. Najafi and his spouse are the trustees,
(ii) 10,200 held directly by Dr. Najafi, and (iii) 46,875 shares issuable
upon exercise of outstanding options which are exercisable as of March 31,
2009 or within 60 days after such
date.
|
|
(3)
|
Includes
(i) 4000 shares held directly by Mr. Paulson and (ii) 62,500 shares
issuable upon exercise of outstanding options which are exercisable as of
March 31, 2009 or within 60 days after such
date.
|
|
(4)
|
Includes
(i) 1,000 shares held by the Behzad and Dorothy Khosrovi Revocable Trust
U/A 7/13/2004, (ii) 135,000 shares of common stock held by FIDELITY
MANAGEMENT TRUST CO FBO of Behzad Khosrovi, and (iii) 214,062 shares
issuable upon exercise of outstanding options which are exercisable as of
March 31, 2009 or within 60 days after such
date.
|
|
(5)
|
Consists
solely of shares held directly by Dr.
Hixson.
|
|
(6)
|
Consists
of (i) 23,144 shares held by the Charles J. Cashion and Martha Diane
Cashion Trust dated July 27, 1988, and (ii) 82,000 shares issuable upon
exercise of outstanding options which are exercisable as of March 31, 2009
or within 60 days after such date.
|
|
(7)
|
Includes
(i) 175,475 shares held by the Anthony and Terry Dailley Trust, of which
Mr. Dailley and his spouse are trustees, (ii) 10,180 shares held by the
Anthony Dailley DDS Profit Sharing Plan, of which Mr. Dailley is the
trustee, (iii) 75,000 shares held directly by Mr. Dailley, and (iv)
104,000 shares issuable upon exercise of outstanding options which are
exercisable as of March 31, 2009 or within 60 days after such
date.
|
|
(8)
|
Includes
(i) 46,908 shares held by the Paul Freiman and Anna Mazzuchi Freiman
Trust, of which Mr. Freiman and his spouse are trustees and (ii) 140,000
shares issuable upon exercise of outstanding options which are exercisable
as of March 31, 2009 or within 60 days after such
date.
|
|
(9)
|
Includes
(i) 500 shares held by the McPherson Family Trust , (ii) 32,008 shares
held directly by Dr. McPherson, and (iii) 71,500 shares issuable upon
exercise of outstanding options which are exercisable as of March 31, 2009
or within 60 days after such date.
|
|
(10)
|
Consists
of (i) 219,219 shares held by the Robert R. Tufts and Joyce A. Tufts Trust
dated September 18, 1987, of which Mr. Tufts and his spouse are trustees,
(ii) 52,000 shares held directly by Robert R. Tufts, and (iii)
100,500 shares issuable upon exercise of outstanding options which are
exercisable as of March 31, 2009 or within 60 days after such
date.
|
15
|
(11)
|
Consists
of (i) 156,854 shares held by the Tony D. Wicks and Anne K. Wicks
Revocable Trust, of which Mr. Wicks and his spouse are trustees and (ii)
104,000 shares issuable upon exercise of outstanding options which are
exercisable as of March 31, 2009 or within 60 days after such
date.
|
|
(12)
|
Includes
925,437 shares of common stock issuable upon exercise of outstanding
options which are exercisable as of March 31, 2009 or within 60 days after
such date.
|
EQUITY
COMPENSATION PLAN INFORMATION
The
following table provides information as of December 31, 2008 with respect to
shares of our common stock that may be issued under existing equity compensation
plans.
|
Plan
Category
|
Number
of Securities to be Issued Upon Exercise of Outstanding Options, Warrants
and Rights
|
Weighted
Average Exercise Price of Outstanding Options, Warrants and
Rights
|
Number
of Securities Remaining Available For Future Issuance under Equity
Compensation Plans (excluding some securities reflected in first
column)
|
|||||||||
|
Equity
compensation plans approved by security holders(1)
|
3,119,988 | $ | 5.70 | 3,707,426 | ||||||||
|
Equity
compensation plans not approved by security holders
|
― | ― | ― | |||||||||
|
Total
|
3,119,988 | $ | 5.70 | 3,707,426 | ||||||||
————————
|
(1)
|
Consists
of our 2002 Stock Option Plan, 2005 Stock Option Plan and 2007 Omnibus
Incentive Plan. No additional option grants are being made
under the 2002 Plan and the 2005 Plan. The 2007 Plan became
effective in October 2007, and 2,000,000 shares were initially reserved
for issuance under that plan and 858,766 were issuable pursuant to the
NovaBay Pharmaceuticals, Inc. 2007 Omnibus Incentive Plan, as amended and
restated.
|
CERTAIN
RELATIONSHIPS
AND
RELATED TRANSACTIONS
Since
December 31, 2008, there has not been any transaction, nor is there any
proposed transaction, to which we were or will be a party, in which the amount
involved exceeded or will exceed the lesser of $120,000 or 1% of the average of
NovaBay’s total assets at the end of the last two completed fiscal
years.
SECTION
16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Under the
federal securities laws, our directors and officers and any persons holding more
than 10% of our common stock are required to report their ownership of our
common stock and any changes in that ownership to the SEC. Specific
due dates for these reports have been established, and we are required to report
in this proxy statement any failure to file by these dates. NovaBay
Pharmaceuticals, Inc. currently issues stock to its directors each time they
convene for a Board or a committee meeting. During the fiscal year
ended December 31, 2008, the Form 4 filings for Messrs. Freiman and Wicks and
Dr. McPherson, for stock grants received by them for their attendance at a
Compensation Committee meeting held on April 1, 2008, and the filings of the
stock grants for their attendance at a Board meeting held on October 1, 2008 for
Messrs. Dailley and Wicks were not filed within two business days of the grant
date. Based solely on our review of copies of the reports on the
Section 16(a) forms received by us with respect to the fiscal year ended
December 31, 2008 and the written representations received from the reporting
persons that no other reports were required, we believe that, except as
indicated in the foregoing sentence, all directors, executive officers and
persons who own more than 10% of our common stock have complied with the
reporting requirements of Section 16(a) and have filed all reports required by
such section.
16
ANNUAL
REPORT
A
copy of our annual report on Form 10-K for the fiscal year ended December 31,
2008 (excluding the exhibits thereto) accompanies the proxy materials being
mailed to all shareholders. The Annual Report is not incorporated into this
proxy statement and is not considered proxy solicitation
material. Shareholders may obtain a copy of the Annual Report and any
of our other filings with the SEC, without charge, by writing to: Secretary,
NovaBay Pharmaceuticals, Inc., 5980 Horton Street, Suite 550, Emeryville,
California 94608. The annual report on Form 10-K (including the
exhibits thereto) is also available on the Securities and Exchange Commission’s
website at www.sec.gov.
DEADLINE
FOR RECEIPT OF
SHAREHOLDER
PROPOSALS OR NOMINATIONS
Shareholders
may present proposals for action at a future meeting or nominate persons for the
election of directors only if they comply with the requirements of the proxy
rules established by the SEC and our bylaws. Pursuant to Rule 14a-8
of the Exchange Act, some shareholders proposals may be eligible for inclusion
in our proxy statement for the 2010 Annual Meeting of Shareholders (the “2010
Annual Meeting”). Shareholder proposals that are intended to be
presented at our 2010 Annual Meeting and included in the proxy statement, form
of proxy and other proxy solicitation materials related to that meeting must be
received by us between January 30, 2010 and February 24, 2010.
If the
date of the 2010 Annual Meeting is not within 30 days of the anniversary of the
2009 Annual Meeting of Shareholders (a situation that we do not anticipate), the
shareholder must submit any such proposal not later than the close of business
on the 10th day following the day on which public announcement of the date of
such meeting is first made. Shareholders are advised to review our bylaws which
contain the advance notice requirements with respect to shareholder proposals
and director nominations.
In
addition, with respect to any proposal that a shareholder presents at the 2010
Annual Meeting that is not submitted for inclusion in our proxy materials
pursuant to Rule 14a-8 under the Exchange Act, the proxy solicited by the Board
for such annual meeting will confer discretionary voting authority to vote on
such shareholder proposal to the extent permitted under Rule 14a-4 under the
Exchange Act.
Shareholder
proposals must be in writing and should be addressed to our corporate Secretary,
at our principal executive offices at 5980 Horton Street, Suite 550, Emeryville,
California 94608. It is recommended that shareholders submitting
proposals direct them to our corporate Secretary and utilize certified mail,
return receipt requested in order to provide proof of timely
receipt. The presiding officer of the Annual Meeting reserves the
right to reject, rule out of order, or take other appropriate action with
respect to any proposal that does not comply with these and other applicable
requirements, including conditions set forth in our bylaws and conditions
established by the SEC.
HOUSEHOLDING
OF PROXY MATERIALS
The SEC
has adopted rules that permit companies and intermediaries (e.g., brokers) to
satisfy the delivery requirements for proxy statements and annual reports with
respect to two or more shareholders sharing the same address by delivering a
single proxy statement addressed to those shareholders. This process, which is
commonly referred to as “householding,” potentially means extra convenience for
shareholders and cost savings for companies.
17
A single
proxy statement may be delivered to multiple shareholders sharing an address
unless contrary instructions have been received from the affected shareholders.
Once you have received notice from your broker that it will be “householding”
communications to your address, “householding” will continue until you are
notified otherwise or until you notify your broker or NovaBay that you no longer
wish to participate in “householding.” If, at any time, you no longer wish to
participate in “householding” and would prefer to receive a separate proxy
statement and annual report in the future you may (1) notify your broker or (2)
direct your written request to our corporate Secretary, NovaBay Pharmaceuticals,
Inc., 5980 Horton Street, Suite 550, Emeryville, California 94608. Shareholders
who currently receive multiple copies of the proxy statement at their address
and would like to request “householding” of their communications should contact
their broker. In addition, NovaBay will promptly deliver, upon written or oral
request to the address or telephone number above, a separate copy of the annual
report and proxy statement to a shareholder at a shared address to which a
single copy of the documents was delivered.
DIRECTIONS
TO SPECIAL MEETING LOCATION
The
Annual Meeting will be held at The Marriot Hotel, 5555 Shellmound Street,
Emeryville, California 94608 at 2:00 p.m. Pacific Time on Thursday, June 4,
2009. Directions to this location are available at
http://www.edocumentview.com/NBY.
OTHER
BUSINESS
The Board
is not aware of any other matter which will be presented for action at the
Annual Meeting other than the matters set forth in this proxy
statement. If any other matter requiring a vote of the shareholders
arises, it is intended that the proxy holders will vote the shares they
represent as the Board may recommend. The enclosed proxy grants the
proxy holders discretionary authority to vote on any such other matters properly
brought before the Annual Meeting.
|
By
Order of the Board of Directors,
|
|
|
/s/ Ramin Najafi, Ph.D.
|
|
|
Ramin
(“Ron”) Najafi, Ph.D.
|
|
|
Chairman
of the Board and Chief Executive
Officer
|
18
PROXY
NOVABAY
PHARMACEUTICALS, INC.
THIS
PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
The
undersigned shareholder of NOVABAY PHARMACEUTICALS, INC. (the “Company”) hereby
appoints RAMIN (“RON”) NAJAFI and THOMAS J. PAULSON, and each of them, proxies
of the undersigned, each with full power to act without the other and with power
of substitution, to represent the undersigned at the Annual Meeting of
Shareholders of NovaBay to be held on Thursday, June 4, 2009 at 2:00 p.m.
Pacific Time at The Marriot Hotel, 5555 Shellmound Street, Emeryville,
California 94608 and at any adjournment or postponement thereof, and to vote all
shares of NovaBay’s common stock held of record by the undersigned on April 13,
2008, with all the powers the undersigned would possess if personally present,
in accordance with the instructions on the reverse hereof.
The
undersigned hereby revokes any other proxy to vote at such Annual Meeting of
Shareholders and hereby ratifies and confirms all that said proxies, and each of
them, may lawfully do by virtue hereof.
(continued
and to be signed on the reverse side)
(continued
from other side)
THIS
PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED IN ACCORDANCE WITH THE INSTRUCTIONS
BELOW, OR IF NO INSTRUCTIONS ARE INDICATED, THIS PROXY WILL BE VOTED FOR ALL
DIRECTORS, AND IN ACCORDANCE WITH THE DISCRETION OF THE PROXY HOLDERS WITH
REGARD TO ANY OTHER MATTERS PROPERLY BROUGHT TO A VOTE AT THE ANNUAL MEETING OR
ANY ADJOURNMENT OR POSTPONEMENT THEREOF.
|
|
1.
|
Election
of Class I Directors.
|
Nominees
standing for election:
|
|
Charles
Cashion
|
□ FOR
|
□ WITHHOLD
AUTHORITY
|
|
|
Alex
McPherson
|
□ FOR
|
□ WITHHOLD
AUTHORITY
|
|
|
Tony
Wicks
|
□ FOR
|
□ WITHHOLD
AUTHORITY
|
|
MARK
HERE FOR ADDRESS CHANGE AND INDICATE NEW ADDRESS
|
□
|
|
MARK
HERE IF YOU PLAN TO ATTEND THE MEETING
|
□
|
|
Date:
|
||
|
Signature
|
||
|
Signature
|
NOTE: This
proxy must be signed exactly as your name appears hereon. Executors,
administrators, trustees, etc., should give full title as such. If
the shareholder is a corporation, a duly authorized officer should sign on
behalf of the corporation and should indicate his or her title.
PLEASE
MARK, SIGN, DATE AND RETURN THIS PROXY CARD PROMPTLY USING THE ENCLOSED
ENVELOPE.